Skip to main content
. 2020 Jun 1;12(6):e8395. doi: 10.7759/cureus.8395

Figure 1. Random blood glucose of the patient over complete treatment cycles.

Figure 1

Months are scaled for the treatment cycle.

DT: durvalumab and tremelimumab combination, D: durvalumab alone, T: tremelimumab alone, IN: ipilimumab and nivolumab combination, DKA: diabetic ketoacidosis.